Advertisement

Breast Cancer Research and Treatment

, Volume 156, Issue 2, pp 237–247 | Cite as

Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer

  • Hirofumi Matsumoto
  • Aye Aye Thike
  • Huihua Li
  • Joe Yeong
  • Si-lin Koo
  • Rebecca Alexandra Dent
  • Puay Hoon Tan
  • Jabed IqbalEmail author
Preclinical study

Abstract

Tumour-infiltrating lymphocytes (TILs) signify immune response to tumour in a variety of cancers including breast cancer. However, earlier studies examining the clinical significance of TILs in breast cancers have generated mixed results. There are only a few that address the relationship between TILs and clinical outcomes in triple-negative breast cancers (TNBC). The aim of this study is to evaluate the clinical significance of TILs that express CD4 + and CD8 + , in TNBC. Immunohistochemical staining of CD4 and CD8 was performed on tissue microarrays of 164 cases of TNBC. TILs were counted separately as intratumoral when within the cancer cell nests (iTILs) and as stromal when within cancer stroma (sTILs). High CD8 + iTILs and sTILs, and CD4 + iTILs correlated with histologic grade. On Kaplan–Meier analysis, a significantly better survival rate was observed in high CD8 + iTIL (disease-free survival, DFS: P = 0.004, overall survival, OS: P = 0.02) and both high CD4 + iTILs (DFS: P = 0.025, OS: P = 0.023) and sTILs (DFS: P = 0.01, OS: P = 0.002). In multivariate analysis, CD8 + iTILs (DFS: P = 0.0095), CD4 + sTILs (DFS: P = 0.0084; OS: P = 0.0118), and CD4 high CD8 high CD8 iTILs (DFS: P = 0.0121; OS: P = 0.0329) and sTILs (DFS: P = 0.0295) showed significantly better survival outcomes. These results suggest that high levels of both CD8 + iTILs and CD4 + sTILs as well as CD4 high CD8 high iTILs and sTILs are independent prognostic factors in TNBC.

Keywords

CD4 CD8 Triple-negative breast cancer (TNBC) Lymphocytes Overall survival 

Notes

Acknowledgments

This study is a part of a research project approved by the SingHealth Centralised Institutional Review Board (CIRB Ref: 2013/664/F) and was funded by the Stratified Medicine Programme Office (Grant No: SMPO201302].

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Reis-Filho JS, Tutt ANJ (2008) Triple negative tumours: a critical review. Histopathology 52:108–118CrossRefPubMedGoogle Scholar
  2. 2.
    Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C (2012) Understanding the biology of triple-negative breast cancer. Ann Oncol Suppl 6:vi13–vi18Google Scholar
  3. 3.
    Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059CrossRefPubMedGoogle Scholar
  5. 5.
    Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success. J Clin Invest 118:1991–2001CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113CrossRefPubMedGoogle Scholar
  7. 7.
    Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) Cd8 + t cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–3494PubMedGoogle Scholar
  8. 8.
    Schumacher K, Haensch W, Röefzaad C, Schlag PM (2001) Prognostic significance of activated cd8(+) t cell infiltrations within esophageal carcinomas. Cancer Res 61:3932–3936PubMedGoogle Scholar
  9. 9.
    Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H (2004) Cd8 + tumor-infiltrating lymphocytes together with cd4 + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28:e26–e31CrossRefPubMedGoogle Scholar
  10. 10.
    Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H (2006) Concurrent infiltration by cd8 + t cells and cd4 + t cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94:275–280CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, Ellis IO, Green AR (2011) Tumor-infiltrating cd8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955CrossRefPubMedGoogle Scholar
  12. 12.
    Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) Cd8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14:R48CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123–133CrossRefPubMedGoogle Scholar
  14. 14.
    Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES (2013) Foxp3-positive regulatory t lymphocytes and epithelial foxp3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 139:381–390CrossRefPubMedGoogle Scholar
  15. 15.
    Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi H, Iwakuma N, Nakagawa S, Fujii T, Sasada T, Yamaguchi R, Yano H, Shirouzu K, Kage M (2013) Foxp3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 1:625–632PubMedPubMedCentralGoogle Scholar
  16. 16.
    Liu S, Foulkes W, Leung S, Gao D, Lau S, Kos Z, Nielsen T (2014) Prognostic significance of foxp3 + tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic t-cell infiltration. Breast Cancer Res 16:432CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lee S, Cho EY, Park YH, Ahn JS, Im YH (2013) Prognostic impact of foxp3 expression in triple-negative breast cancer. Acta Oncol 52:73–81CrossRefPubMedGoogle Scholar
  18. 18.
    Lee AHS, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR (2006) Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 48:692–701CrossRefPubMedGoogle Scholar
  19. 19.
    García-Martínez E, Gil G, Benito A, González-Billalabeitia E, Conesa M, García G, García-Garre E, Vicente V, Ayala D (2014) Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res 16:488CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Hunborg P, Varvares M, Hoft D, Hsueh E, Peng G (2015) Cd4 + and cd8 + t cells have opposing roles in breast cancer progression and outcome. Oncotarget 6:17462–17478CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Al-Hassan AA, Al-Ghurabi BH, Al-Karkhi IH (2012) Prognostic value of proinflammatory cytokines in breast cancer. J Biomol Res Ther 1:104Google Scholar
  22. 22.
    Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, Miao X, Tang Z (2014) Intratumoral cd8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS ONE 9:10Google Scholar
  23. 23.
    Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, Pudelko M, Szynglarewicz B, Szelachowska J, Zolnierek A, Kornafel J (2009) The prognostic role of tumor-infiltrating cd4 and cd8 t lymphocytes in breast cancer. Anticancer Res 29:2445–2451PubMedGoogle Scholar
  24. 24.
    Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD (2011) Prognostic significance of cd8 + t lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58:1107–1116PubMedGoogle Scholar
  25. 25.
    Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E (2015) Tumor-infiltrating lymphocytes in breast cancer: ready for prime time. J Clin Oncol 33:1298–1299CrossRefPubMedGoogle Scholar
  26. 26.
    Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K (2014) The value of tumor infiltrating lymphocytes (tils) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS ONE 9:e115103CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Plos ONE Staff (2015) Correction: the value of tumor infiltrating lymphocytes (tils) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS ONE 10:e0119243CrossRefGoogle Scholar
  28. 28.
    Yu P, Fu YX (2006) Tumor-infiltrating t lymphocytes: friends or foes. Lab Invest 86:231–245CrossRefPubMedGoogle Scholar
  29. 29.
    Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, Caldas C (2010) Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 10:604CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumour-infiltrating cd8 + lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AHS (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45:1780–1787CrossRefPubMedGoogle Scholar
  32. 32.
    Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, Neville AM (2011) Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS ONE 6:e17876CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nolè F, Rotmensz N, Goldhirsch A (2011) Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 22:98–103CrossRefPubMedGoogle Scholar
  34. 34.
    Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Karpf AR, James SA, Ambrosone CB, O’Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K (2012) Ny-eso-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS ONE 7:e38783CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109:2796–2801CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Scandiuzzi L, Ghosh K, Zang X (2011) T cell costimulation and coinhibition: genetics and disease. Discov Med 12:119–128PubMedPubMedCentralGoogle Scholar
  37. 37.
    Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S (2006) The b7-h1 (pd-l1) t lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8:190–198CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S (2007) Expression of b7-h1 in breast cancer patients is strongly associated with high proliferative ki-67-expressing tumor cells. Int J Cancer 121:751–758CrossRefPubMedGoogle Scholar
  39. 39.
    Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (il)-6 in cancer metastasis to bone: potential of anti-il-6 therapies. Cancer Manag Res 3:177–189PubMedPubMedCentralGoogle Scholar
  40. 40.
    Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG (2012) Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget 3:988–997CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Singh M, Ramos I, Asafu-Adjei D, Quispe-Tintaya W, Chandra D, Jahangir A, Zang X, Aggarwal BB, Gravekamp C (2013) Curcumin improves the therapeutic efficacy of listeria(at)-mage-b vaccine in correlation with improved t-cell responses in blood of a triple-negative breast cancer model 4t1. Cancer Med 2:571–582CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) Cd4+ follicular helper t cell infiltration predicts breast cancer survival. J Clin Invest 123:2873–2892CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, Easterbrook P, Grey P, Smith D, McMichael AJ, Cooper DA, Rowland-Jones SL, Kelleher AD (2002) Characterization of cd4(+) ctls ex vivo. J Immunol 168:5954–5958CrossRefPubMedGoogle Scholar
  44. 44.
    Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J, Shi J, Fu B, Liu Z, Zhang JY, Jin L, Zhao Y, Lau GKK, Zhao J, Wang FS (2013) Impairment of cd4+ cytotoxic t cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 58:139–149CrossRefPubMedGoogle Scholar
  45. 45.
    West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13:R126CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (tils) in breast cancer: recommendations by an international tils working group 2014. Ann Oncol 26:259–271CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Hirofumi Matsumoto
    • 1
  • Aye Aye Thike
    • 2
  • Huihua Li
    • 3
  • Joe Yeong
    • 2
    • 4
  • Si-lin Koo
    • 5
  • Rebecca Alexandra Dent
    • 5
  • Puay Hoon Tan
    • 2
  • Jabed Iqbal
    • 2
    Email author
  1. 1.Department of PathologyRyukyu University HospitalOkinawaJapan
  2. 2.Department of PathologySingapore General HospitalSingaporeSingapore
  3. 3.Division of ResearchSingapore General HospitalSingaporeSingapore
  4. 4.Singapore Immunology Network, Agency of Science, Technology and ResearchSingaporeSingapore
  5. 5.Department of Medical OncologyNational Cancer CentreSingaporeSingapore

Personalised recommendations